Michael H. A. Roehrl, MD, Ph., University of Toronto, Toronto, ON
Sylvia L. Asa, MD, PhD, University of Toronto, Toronto, ON
Massimo F. Loda, MD, Dana Farber Cancer Institute, Boston, MA
The practice of personalized predictive pathology as the central diagnostic medical specialty of the future is currently undergoing major transformations in the age of OMIC technologies, including genomics, transcriptomics, proteomics, and metabolomics.
Our Short Course will provide a basic introduction for practicing pathologists, pathologists in training, and laboratory professionals to the fundamentals of these groundbreaking technologies and demonstrate their potential for applications in personalized tissue-based diagnostics. We will review the fundamentals of OMIC technologies as they relate directly to the future of the practice of personalized pathology. We will be discussing next gen genome and transcriptome sequencing, the significance of cancer exome alterations for personalized treatment decision making (and the key role of pathology), and mass spectrometry as an up and coming exciting technology to examine the proteomes and metabolomes of diseased tissues. We will also introduce pathologists to the basic concepts and terminology of associated key enabling tools such as bioinformatics and digital pathology.
Pathologists and laboratory professionals will be the key drivers for implementing these enabling technologies and will thus transform the practice of personalized systems medicine of the future. This course will equip participants with the key tools for successfully mastering the future of pathology. No previous exposure or knowledge of OMIC technologies is assumed. Registrants will be able to view pre-meeting materials consisting of advance reading material, case studies and a problem set on the USCAP website. A syllabus will be given to all registrants at the meeting, and after meeting material will be posted on the USCAP website for registrant access.